These also included new RTK drug targets for breast carcinoma, such as the discoidin domain receptor (DDR1), which is involved in the activation of cell proliferation, survival, ECM remodeling, migration and invasion pathways29. The gene discussed is DDR1; the disease is breast carcinoma.